NPSP795: Phase IIa started

NPS began an open-label, dose-escalation, U.S. Phase IIa trial to evaluate IV NPSP795 in up to 12 patients with ADH, a genetic disorder of calcium homeostasis. NPSP795 was discovered using NPS’s calci...